Equities analysts forecast that Zafgen (NASDAQ:ZFGN) will report earnings per share (EPS) of ($0.59) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zafgen’s earnings. Zafgen reported earnings per share of ($0.49) during the same quarter last year, which would suggest a negative year-over-year growth rate of 20.4%. The company is expected to report its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Zafgen will report full-year earnings of ($2.50) per share for the current year. For the next year, analysts anticipate that the business will report earnings of ($1.64) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Zafgen.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.06).
In related news, insider Thomas E. Hughes sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 23.70% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its position in Zafgen by 139,086.7% in the first quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 20,863 shares in the last quarter. A.R.T. Advisors LLC grew its position in Zafgen by 62.9% in the first quarter. A.R.T. Advisors LLC now owns 23,053 shares of the biopharmaceutical company’s stock valued at $171,000 after acquiring an additional 8,904 shares in the last quarter. Element Capital Management LLC acquired a new stake in Zafgen in the first quarter valued at approximately $174,000. Algert Global LLC acquired a new stake in Zafgen in the first quarter valued at approximately $195,000. Finally, Tibra Equities Europe Ltd acquired a new stake in Zafgen in the first quarter valued at approximately $377,000. 52.24% of the stock is owned by hedge funds and other institutional investors.
NASDAQ ZFGN opened at $6.45 on Monday. Zafgen has a 12 month low of $6.50 and a 12 month high of $6.60. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.27 and a quick ratio of 12.27. The stock has a market cap of $181.37 million, a PE ratio of -3.39 and a beta of -0.55.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.